Patents Assigned to Inscripta, Inc.
  • Nucleic acid-guided nucleases
    Patent number: 11220697
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: July 28, 2021
    Date of Patent: January 11, 2022
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Engineered enzyme
    Patent number: 11214781
    Abstract: The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from Eubacterium rectale.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: January 4, 2022
    Assignee: Inscripta, Inc.
    Inventors: Juhan Kim, Benjamin Mijts
  • Automated cell processing methods, modules, instruments, and systems
    Patent number: 11203751
    Abstract: In an illustrative embodiment, automated multi-module cell editing instruments are provided to automate multiple edits into nucleic acid sequences inside one or more cells.
    Type: Grant
    Filed: June 1, 2021
    Date of Patent: December 21, 2021
    Assignee: Inscripta, Inc.
    Inventors: Jorge Bernate, Kevin Ness, Phillip Belgrader, Don Masquelier, Ryan Gill
  • Methods for increasing observed editing in bacteria
    Patent number: 11203762
    Abstract: The present disclosure relates to methods for increasing observed editing rates in the surviving bacteria cells.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: December 21, 2021
    Assignee: Inscripta, Inc.
    Inventors: Tian Tian, Eileen Spindler, Charles Johnson, Clint Davis
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11198857
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: December 14, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • Mad nucleases
    Patent number: 11193115
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: December 7, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Mad nucleases
    Patent number: 11174471
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 16, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Simultaneous multiplex genome editing in yeast
    Patent number: 11149260
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: October 19, 2021
    Assignee: Inscripta, Inc.
    Inventors: Skylar Stefani, Tian Tian, Miles Gander
  • Detection of nuclease edited sequences in automated modules and instruments
    Patent number: 11142740
    Abstract: The present disclosure provides automated modules and instruments for improved detection of nuclease genome editing of live cells. The disclosure provides improved modules—including high throughput modules—for screening cells that have been subjected to editing and identifying and selecting cells that have been properly edited.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: October 12, 2021
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Michael Graige, Richard Fox, Eileen Spindler, Amy Hiddessen, Phillip Belgrader, Don Masquelier, Bruce Chabansky
  • Simultaneous multiplex genome editing in yeast
    Patent number: 11136572
    Abstract: The present disclosure provides compositions of matter, methods and instruments for editing nucleic acids in live yeast cells.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: October 5, 2021
    Assignee: Inscripta, Inc.
    Inventors: Miles Gander, Tian Tian, Skylar Stefani, Patrick Westfall
  • Nucleic acid-guided nucleases
    Patent number: 11130970
    Abstract: Disclosed herein are nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Disclosed herein are engineered non-naturally occurring nucleic acid-guided nucleases, guide nucleic acids, and targetable nuclease systems, and methods of use. Targetable nuclease systems can be used to edit genetic targets, including recursive genetic engineering and trackable genetic engineering methods.
    Type: Grant
    Filed: February 18, 2021
    Date of Patent: September 28, 2021
    Assignee: Inscripta, Inc.
    Inventors: Andrew Garst, Ryan T. Gill, Tanya Elizabeth Warnecke Lipscomb
  • Flow through electroporation modules and instrumentation
    Patent number: 11118153
    Abstract: The present disclosure provides a flow-through electroporation device configured for use in an automated multi-module cell processing environment and configured to decrease cell processing time and the risk of clogging.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: September 14, 2021
    Assignee: Inscripta, Inc.
    Inventors: Nathan Bade, Jorge Bernate, Phillip Belgrader, Don Masquelier
  • Cascade/dCas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
    Patent number: 11104890
    Abstract: The present disclosure relates to methods and compositions that allow one to identify in vivo edited cells when employing nucleic-acid guided editing. Additionally provided are automated multi-module instruments for performing editing and selection methods and using the compositions.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: August 31, 2021
    Assignee: Inscripta, Inc.
    Inventors: Aamir Mir, Andrew Garst, Stephen Federowicz, Kyle Seamon
  • MAD nucleases
    Patent number: 11085030
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: August 10, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon
  • Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
    Patent number: 11085131
    Abstract: The present disclosure provides shuttle vectors for editing exogenous polynucleotides in heterologous live cells, as well as automated methods, modules, and multi-module cell editing instruments and systems for performing the editing methods.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: August 10, 2021
    Assignee: Inscripta, Inc.
    Inventors: Richard Fox, Daniel Held
  • Genome-wide rationally-designed mutations leading to enhanced lysine production in
    Patent number: 11078458
    Abstract: The present disclosure relates to various different types of variants in E. coli coding and noncoding regions leading to enhanced lysine production for, e.g., supplements and nutraceuticals.
    Type: Grant
    Filed: January 26, 2021
    Date of Patent: August 3, 2021
    Assignee: Inscripta, Inc.
    Inventors: Richard Fox, Daniel Held, Eric Abbate, Michael Clay, Katherine Krouse, Nandini Krishnamurthy, Krishna Yerramsetty
  • Instruments, modules, and methods for improved detection of edited sequences in live cells
    Patent number: 11072774
    Abstract: The present disclosure provides instruments, modules and methods for improved detection of edited cells following nucleic acid-guided nuclease genome editing. The disclosure provides improved automated instruments that perform methods—including high throughput methods—for screening cells that have been subjected to editing and identifying cells that have been properly edited.
    Type: Grant
    Filed: February 13, 2021
    Date of Patent: July 27, 2021
    Assignee: Inscripta, Inc.
    Inventors: Phillip Belgrader, Don Masquelier, Andrew Garst, Richard Fox
  • Increased nucleic-acid guided cell editing in yeast
    Patent number: 11066675
    Abstract: The present disclosure provides methods to increase the percentage of edited yeast cells in a cell population using nucleic-acid guided editing, and automated multi-module instruments for performing these methods.
    Type: Grant
    Filed: January 2, 2021
    Date of Patent: July 20, 2021
    Assignee: Inscripta, Inc.
    Inventors: Krishna Kannan, Miles Gander, Eileen Spindler, Paul Hardenbol
  • Curing for recursive nucleic acid-guided cell editing
    Patent number: 11053507
    Abstract: The present disclosure provides automated multi-module instrumentation and automated methods for performing recursive editing of live cells with curing of editing vectors from prior rounds of editing.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: July 6, 2021
    Assignee: Inscripta, Inc.
    Inventors: Tian Tian, Charles Johnson, Eileen Spindler
  • MAD nucleases
    Patent number: 11053485
    Abstract: The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: July 6, 2021
    Assignee: Inscripta, Inc.
    Inventors: Benjamin Mijts, Juhan Kim, Aamir Mir, Andrew Garst, Kyle Seamon